Establishment and validation of a recursive partitioning analysis based prognostic model for guiding re-radiotherapy in locally recurrent nasopharyngeal carcinoma patients

•A total of 531 patients with local recurrence nasopharyngeal carcinoma (lrNPC) were retrospectively reviewed.•We established and validated an integrated prognostic model for lrNPC patients.•Three risk groups were derived from an RPA model that combined rT stage and EBV DNA.•Re-radiotherapy could be...

Full description

Saved in:
Bibliographic Details
Published in:Radiotherapy and oncology 2022-03, Vol.168, p.61-68
Main Authors: Sun, Xue-Song, Zhu, Man-Yi, Wen, Dong-Xiang, Luo, Dong-Hua, Sun, Rui, Chen, Qiu-Yan, Mai, Hai-Qiang
Format: Article
Language:English
Subjects:
DNA, Viral
EBV DNA
Epstein-Barr Virus Infections
Herpesvirus 4, Human - genetics
Humans
Nasopharyngeal carcinoma
Nasopharyngeal Carcinoma - pathology
Nasopharyngeal Neoplasms - pathology
Neoplasm Recurrence, Local
Prognosis
Radiotherapy
Recurrence
Retrospective Studies
Survival
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•A total of 531 patients with local recurrence nasopharyngeal carcinoma (lrNPC) were retrospectively reviewed.•We established and validated an integrated prognostic model for lrNPC patients.•Three risk groups were derived from an RPA model that combined rT stage and EBV DNA.•Re-radiotherapy could benefit patients in the low and intermediate-risk subgroups.•No association between re-RT and survival benefit was found in the high-risk. subgroup. In this study, we aimed to establish and validate an integrated prognostic model for locally recurrent nasopharyngeal carcinoma (lrNPC) patients, and evaluate the benefit of re-radiotherapy (re-RT) in patients with different risk levels. In total, 531 patients with lrNPC were retrospectively reviewed in this study, including 271 patients from 2006 to 2012 as the training cohort and 260 patients from 2013 to 2016 as the validation cohort. Overall survival (OS) was the primary endpoint. Multivariate analysis was performed to select the significant prognostic factors (P 
ISSN:0167-8140
1879-0887
DOI:10.1016/j.radonc.2022.01.026